Akebia Therapeutics Inc (NASDAQ: AKBA) has announced the preliminary results for the full year 2018 after the completion of the company's business combination with Keryx Biopharmaceuticals, Inc. (Keryx) on December 12, 2018 and the time required to complete the allocation of the merger consideration to the fair value of the acquired assets and liabilities as well as the assessment of the associated tax impacts. AKBA stock rose over 2.1% on March 19 th, 2019 (as of 11:18 am GMT-4; Source: Google finance)